Tarsus Pharmaceuticals, Inc.
TARS Nasdaq
SEC CIK 1819790
Follow Tarsus Pharmaceuticals
Weekly email: filings, results
Revenue, last quarter
$194.6M
+63.9% vs same quarter last year
Net income
−$668.3M
−5210.6% vs same quarter last year
EPS, diluted
−$14.40
−4700% vs same quarter last year
Operating cash flow
−$6M
−132.9% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $451.4M | −$66M |
| FY24 | $183M | −$116M |
| FY23 | $17.4M | −$136M |
| FY22 | $25.8M | −$62.1M |
| FY21 | $57M | −$13.8M |
| FY20 | $0 | −$26.8M |
| FY19 | - | −$4.7M |
| FY18 | - | −$1.3M |
| FY17 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −15.7% | −14.6% |
| FY24 | −65.9% | −63.4% |
| FY23 | −820.5% | −779.5% |
| FY22 | −242.9% | −240.5% |
| FY21 | −21.3% | −24.2% |
| FY20 | - | - |
| FY19 | - | - |
| FY18 | - | - |
| FY17 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$22.3M |
| FY24 | −$84.6M |
| FY23 | −$119M |
| FY22 | −$49.5M |
| FY21 | $3.2M |
| FY20 | −$21.6M |
| FY19 | −$3.8M |
| FY18 | - |
| FY17 | - |
- Tarsus Pharmaceuticals
- Healthcare median
Show the numbers
| Year | Tarsus Pharmaceuticals | Healthcare median |
|---|---|---|
| FY25 | −14.6% | −30.6% |
| FY24 | −63.4% | −47% |
| FY23 | −779.5% | −58% |
| FY22 | −240.5% | −80.4% |
| FY21 | −24.2% | −71.8% |
| FY20 | - | −62.2% |
| FY19 | - | −46.2% |
| FY18 | - | −49.6% |
| FY17 | - | −45.9% |